

Disclaimer

- This presentation has been prepared by Duni AB (the "Company") solely for use at this investor presentation and is furnished to you solely for your information and may not be reproduced or redistributed, in whole or in part, to any other person. By attending the meeting where this presentation is made, or by reading the presentation slides, you agree to be bound by the following limitations.
- This presentation is not for presentation or transmission into the United States or to any U.S. person, as that term is defined under Regulation S promulgated under the Securities Act of 1933, as amended.
- This presentation contains various forward-looking statements that reflect management's current views with respect to future events and financial and operational performance. The words "believe," "expect," "anticipate," "intend," "may," "plan," "estimate," "should," "could," "aim," "target," "might," or, in each case, their negative, or similar expressions identify certain of these forward-looking statements. Others can be identified from the context in which the statements are made. These forward-looking statements involve known and unknown risks, uncertainties and other factors, which are in some cases beyond the Company's control and may cause actual results or performance to differ materially from those expressed or implied from such forward-looking statements. These risks include but are not limited to the Company's ability to operate profitably, maintain its competitive position, to promote and improve its reputation and the awareness of the brands in its portfolio, to successfully operate its growth strategy and the impact of changes in pricing policies, political and regulatory developments in the markets in which the Company operates, and other risks.
- The information and opinions contained in this document are provided as at the date of this presentation and are subject to change without notice.
- No representation or warranty (expressed or implied) is made as to, and no reliance should be placed on, the fairness, accuracy or completeness of the information contained herein. Accordingly, none of the Company, or any of its principal shareholders or subsidiary undertakings or any of such person's officers or employees accepts any liability whatsoever arising directly or indirectly from the use of this document.

2012 Q4 Highlights


- Professional underlying demand stabilized
 - Sales almost on par with last year in comparable currency rates.
 - Maintained focus on inventory reduction with negative absorption effects as a consequence.
- Consumer delays in implementation of new contracts
 - Some delay in two important new contracts expected to be in full force in Q1 2013.
 - Costs of implementing contracts relatively high in the quarter.
- Tissue Initiated closing of one of three factories in Dalsland
 - Unsatisfactory profitability in factory supplying hygiene business.
 - Closure will not effect Duni's future EBIT, but improve net debt. Restructuring cost taken of SEK 83 m in Q4.
- Other restructuring cost of SEK 24 m in the quarter
 - SEK 6 m related to previous announced program.
 - SEK 18 m related to change of CEO, write downs and restructuring in the export markets.
- Net debt at historically low level as a result of improvements in Working Capital and lower CAPEX.

- Net sales SEK 1 031 m (1 063)
- Underlying operating income SEK 128 m
 (151)
- Underlying operating margin 12.4% (14.2%)



Market Outlook

- HORECA market long-term growing in line or slightly above GDP.
 - Positive eating out trend.
 - Higher growth in take-away sector.
- Macro statistics stabilizing, but growth not to be expected in short to mid term.
 - Economic crisis creates uncertainty in consumer confidence, influencing Duni's end customers.
 - Duni's major markets including Germany and Benelux with flat or minor decrease in volume.
- Pulp price flat, but expected to slowly increase. Plastics on all time high levels in EUR.



HoReCa Sales Development

Germany (Nov 2012)

| Wirtschaftsbereich | 11/201 | 2 zu 11/2011 | 01-11/2012 zu 01-11/2011 | | |
|-----------------------|---------|--------------|--------------------------|------|--|
| | nominal | real | nominal | real | |
| Gastgewerbe insgesamt | 2,0 | 0,2 | 2,3 | 0,3 | |
| Beherbergung | 1,7 | 0,6 | 3,2 | 1,4 | |
| Gastronomie | 2,1 | 0,0 | 1,7 | -0,3 | |

Source: destatis



Restaurant Sales Development

Sweden (Dec 2011 – Dec 2012)




 \Box +2,7% in volume in Dec and +2,6% in value.





Professional

-Lower sales and EBIT mainly impacted by currency



Geographical split – sales Q4 2012


| Net sales Professional | Q4 2012 | Q4 2011 | Growth | Growth at fixed exchange rates |
|---------------------------|---------|---------|--------|--------------------------------|
| Nordic | 173 | 179 | -3.4% | -3.4% |
| Central Europe | 424 | 446 | -4.9% | -0.9% |
| South & East Europe | 117 | 117 | 0.0% | 4.3% |
| Rest of the World | 9 | 9 | 0.0% | 0.0% |
| TOTAL | 722 | 750 | -3.7% | -0.5% |

- Stable development in major markets.
- Evolin launch continues with new colors.
- 1) Excluding non-recurring costs and market valuation of derivatives



Consumer

Improvement in sales trend



Geographical split - sales Q4 2012

| Net sales Consumer | Q4 2012 | Q4 2011 | Growth | Growth at fixed exchange rates |
|------------------------|---------|---------|---------------|--------------------------------|
| Nordic | 28 | 25 | 12.0% | 12.0% |
| Central Europe | 161 | 177 | -9.0% | -6.2% |
| South & East Europe | 8 | 6 | 33.3% | 50.0% |
| Rest of the World | 0 | 1 | -100.0% | -100.0% |
| TOTAL | 197 | 209 | -5. 7% | -2.8% |


• Improvement from previous quarters, but delay in implementation of new accounts.

1) Excluding non-recurring costs and market valuation of derivatives



Tissue

Low capacity utilization



Sales mix Q4 2012 External 47% Internal 53% • Decision to initiate closing of hygiene business. • Restructuring cost of 83 MSEK. • Insignificant effect on Duni's future EBIT.





Operating Margin (underlying) 12.4% - Significant Restructuring cost

| SEKm | Q4 2012 | Q4 2011 | FY 2012 | FY 2011 |
|-----------------------------------|------------|------------|---------|------------|
| | | | | |
| Net sales | 1 031 | 1 063 | 3 669 | 3 807 |
| Gross profit | 267 | 315 | 945 | 1 031 |
| Gross margin | 25.9% | 29.7% | 25.8% | 27.1% |
| Selling expenses | -111 | -109 | -438 | -441 |
| Administrative expenses | -56 | -45 | -177 | -172 |
| R&D expenses | -5 | -9 | -26 | -30 |
| Other operating net | -75 | -9 | -77 | 0 |
| Operating income (reported) | 21 | 144 | 228 | 388 |
| Non-recurring items ¹⁾ | -107 | -7 | -113 | -16 |
| Operating income (underlying) | 128 | 151 | 340 | 404 |
| Operating margin (underlying) | 12.4% | 14.2% | 9.3% | 10.6 % |
| Financial net | -5 | -9 | -25 | -30 |
| Taxes | -32 | -36 | -79 | -98 |
| Net income | -16 | 98 | 124 | 261 |
| Earnings per share | -0.35 | 2.09 | 2.63 | 5.54 |

¹⁾ Restructuring costs and market valuation of derivatives



Lower Capacity Utilization in Q4 and FY 2012

| SEKm | | Q4 2012 | Q4 2011 | FY 2012 | FY 2011 |
|--------------|--------------------------------|------------|------------|------------|------------|
| Professional | Net sales | 722 | 750 | 2 682 | 2 766 |
| | Operating income ¹⁾ | 108 | 121 | 336 | 357 |
| | Operating margin | 14.9% | 16.1% | 12.5% | 12.9% |
| Consumer | Net sales | 197 | 209 | 551 | 612 |
| | Operating income ¹⁾ | 19 | 24 | 5 | 21 |
| | Operating margin | 9.4% | 11.7% | 0.9% | 3.4% |
| Tissue | Net sales | 111 | 104 | 436 | 428 |
| | Operating income ¹⁾ | 1 | 6 | -1 | 25 |
| | Operating margin | 1.3% | 5.4% | -0.2% | 5.9% |
| Duni | Net sales | 1 031 | 1 063 | 3 669 | 3 807 |
| | Operating income ¹⁾ | 128 | 151 | 340 | 404 |
| | Operating margin | 12.4% | 14.2% | 9.3% | 10.6% |

¹⁾ Excluding non-recurring cost and market valuation of derivates



Continued strong Cash Flow

| SEKm | Q4 2012 | Q4 2011 | FY 2012 | FY 2011 |
|------------------------------------------|------------|-------------|-------------|-------------|
| EBITDA ¹⁾ Capital expenditure | 156 -26 | 177 -200 | 452 -113 | 511 -377 |
| Change in; | | | | |
| Inventory | 90 | 55 | 66 | -37 |
| Accounts receivable | -9 | -13 | 20 | -36 |
| Accounts payable | 26 | -4 | 7 | -8 |
| Other operating working capital | -16 | -22 | -17 | 23 |
| Change in working capital | 91 | 16 | 76 | -58 |
| Operating cash flow | 221 | -7 | 415 | 76 |

¹⁾ Excluding non-recurring costs and market valuation of derivatives



Net Debt at all time low

| SEKm | 2012 | 2011 | 2010 |
|------------------------------------------------------|-------|-------|-------|
| Goodwill | 1 199 | 1 199 | 1 199 |
| Tangible and intangible fixed assets | 795 | 888 | 632 |
| Net financial assets ¹⁾ | 185 | 210 | 253 |
| Inventories | 387 | 470 | 437 |
| Accounts receivable | 624 | 663 | 634 |
| Accounts payable | -301 | -302 | -315 |
| Other operating assets and liabilities ³⁾ | -282 | -300 | -266 |
| Net assets | 2 607 | 2 827 | 2 573 |
| Net debt | 555 | 745 | 582 |
| Equity | 2 051 | 2 082 | 1 991 |
| Equity and net debt | 2 607 | 2 827 | 2 573 |
| ROCE ²⁾ | 14% | 17% | 19% |
| ROCE ²⁾ w/o Goodwill | 28% | 29% | 40% |
| Net debt / Equity | 27% | 36% | 29% |
| Net debt / EBITDA ²⁾ | 1.2 | 1.5 | 1.1 |

- 1) Deferred tax assets and liabilities + Income tax receivables and payables
- 2) Excluding non-recurring costs and market valuation of derivatives
- 3) Including restructuring provision and derivatives



Financial Targets

2012

Sales growth > 5%

 Organic growth of 5% over a business cycle

-1.6%

 Consider acquisitions to reach new markets or to strengthen current market positions (at fixed exchange rates)

EBIT margin > 10%

Underlying

Top line growth – premium focus

9.3%

 Improvements in manufacturing, sourcing and logistics

Dividend payout ratio 40+%

Target at least 40% of net profit

3.50 SEK per share (proposal)



